Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tracking clonal evolution of drug resistance in ovarian cancer patients by exploiting structural variants in cfDNA.
Williams MJ, Vázquez-García I, Tam G, Wu M, Varice N, Havasov E, Shi H, Satas G, Lees HJ, Lee JJ, Myers MA, Zatzman M, Rusk N, Ali E, Shah RH, Berger MF, Mohibullah N, Lakhman Y, Chi DS, Abu-Rustum NR, Aghajanian C, McPherson A, Zamarin D, Loomis B, Weigelt B, Friedman CF, Shah SP. Williams MJ, et al. Among authors: weigelt b. bioRxiv [Preprint]. 2024 Aug 23:2024.08.21.609031. doi: 10.1101/2024.08.21.609031. bioRxiv. 2024. PMID: 39229105 Free PMC article. Preprint.
Ongoing genome doubling promotes evolvability and immune dysregulation in ovarian cancer.
McPherson A, Vázquez-García I, Myers MA, Zatzman M, Al-Rawi D, Weiner A, Freeman S, Mohibullah N, Satas G, Williams MJ, Ceglia N, Zhang AW, Li J, Lim JLP, Wu M, Choi S, Havasov E, Grewal D, Shi H, Kim M, Schwarz R, Kaufmann T, Dinh KN, Uhlitz F, Tran J, Wu Y, Patel R, Ramakrishnan S, Kim D, Clarke J, Green H, Ali E, DiBona M, Varice N, Kundra R, Broach V, Gardner GJ, Roche KL, Sonoda Y, Zivanovic O, Kim SH, Grisham RN, Liu YL, Viale A, Rusk N, Lakhman Y, Ellenson LH, Tavaré S, Aparicio S, Chi DS, Aghajanian C, Abu-Rustum NR, Friedman CF, Zamarin D, Weigelt B, Bakhoum SF, Shah SP. McPherson A, et al. Among authors: weigelt b. bioRxiv [Preprint]. 2024 Jul 15:2024.07.11.602772. doi: 10.1101/2024.07.11.602772. bioRxiv. 2024. PMID: 39071261 Free PMC article. Preprint.
Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity.
Brodeur MN, Dopeso H, Zhu Y, Longhini ALF, Gazzo A, Sun S, Koche R, Qu R, Hamard PJ, Bykov Y, Green H, Chiappinelli KB, Ozsoy MA, Basili T, Gardner R, Walderich S, DeStanchina E, Greenbaum B, Gönen M, Weigelt B, Zamarin D. Brodeur MN, et al. Among authors: weigelt b. bioRxiv [Preprint]. 2023 Aug 11:2023.08.08.552544. doi: 10.1101/2023.08.08.552544. bioRxiv. 2023. PMID: 37609261 Free PMC article. Preprint.
Spatial molecular profiling of mixed invasive ductal-lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations.
Shah OS, Nasrazadani A, Foldi J, Atkinson JM, Kleer CG, McAuliffe PF, Johnston TJ, Stallaert W, da Silva EM, Selenica P, Dopeso H, Pareja F, Mandelker D, Weigelt B, Reis-Filho JS, Bhargava R, Lucas PC, Lee AV, Oesterreich S. Shah OS, et al. Among authors: weigelt b. bioRxiv [Preprint]. 2024 Jun 16:2023.09.09.557013. doi: 10.1101/2023.09.09.557013. bioRxiv. 2024. Update in: Proc Natl Acad Sci U S A. 2024 Jul 30;121(31):e2322068121. doi: 10.1073/pnas.2322068121. PMID: 38915645 Free PMC article. Updated. Preprint.
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.
Green AK, Zhou Q, Iasonos A, Zammarrelli WA, Weigelt B, Ellenson LH, Chhetri-Long R, Shah P, Loh J, Hom V, Selenica P, Erinjeri J, Petkovska I, Chandarlapaty S, Cohen S, Grisham R, Konner J, Rubinstein MM, Tew W, Troso-Sandoval T, Aghajanian C, Makker V. Green AK, et al. Among authors: weigelt b. Clin Cancer Res. 2024 Nov 19. doi: 10.1158/1078-0432.CCR-24-1999. Online ahead of print. Clin Cancer Res. 2024. PMID: 39561275
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion.
Kudo R, Safonov A, Jones C, Moiso E, Dry JR, Shao H, Nag S, da Silva EM, Yildirim SY, Li Q, O'Connell E, Patel P, Will M, Fushimi A, Benitez M, Bradic M, Fan L, Nakshatri H, Sudhan DR, Denz CR, Reis-Filho JS, Goel S, Koff A, Weigelt B, Khan QJ, Razavi P, Chandarlapaty S. Kudo R, et al. Among authors: weigelt b. Cancer Cell. 2024 Nov 11;42(11):1983. doi: 10.1016/j.ccell.2024.10.013. Cancer Cell. 2024. PMID: 39532066 Free article. No abstract available.
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion.
Kudo R, Safonov A, Jones C, Moiso E, Dry JR, Shao H, Nag S, da Silva EM, Yildirim SY, Li Q, O'Connell E, Patel P, Will M, Fushimi A, Benitez M, Bradic M, Fan L, Nakshatri H, Sudhan DR, Denz CR, Huerga Sanchez I, Reis-Filho JS, Goel S, Koff A, Weigelt B, Khan QJ, Razavi P, Chandarlapaty S. Kudo R, et al. Among authors: weigelt b. Cancer Cell. 2024 Nov 11;42(11):1919-1935.e9. doi: 10.1016/j.ccell.2024.09.009. Epub 2024 Oct 10. Cancer Cell. 2024. PMID: 39393354 Free article.
Lymph node metastases in endometrial carcinoma: A modern assessment in the era of sentinel lymph node mapping and molecular subtyping.
Praiss AM, Dagher C, Zhou Q, Iasonos A, Rios-Doria E, Abu-Rustum NR, Chiang S, Momeni-Boroujeni A, Weigelt B, Ellenson LH, Leitao MM Jr, Mueller JJ. Praiss AM, et al. Among authors: weigelt b. Gynecol Oncol. 2024 Sep 26;191:37-44. doi: 10.1016/j.ygyno.2024.09.012. Online ahead of print. Gynecol Oncol. 2024. PMID: 39332279
363 results